Thrombectomy within 8 Hours after Symptom Onset in Ischemic Stroke
Source: View publication →
In patients with acute ischemic stroke due to anterior circulation occlusion treated within 8 hours of onset, mechanical thrombectomy with a stent retriever plus medical therapy significantly reduced global disability and increased functional independence compared to medical therapy alone.
Key Findings
Study Design
Study Limitations
Clinical Significance
REVASCAT was one of the five landmark 2015 trials that definitively established mechanical thrombectomy as the standard of care for acute ischemic stroke caused by anterior circulation large vessel occlusions. By demonstrating profound functional benefits up to 8 hours from symptom onset without an increase in hemorrhagic complications, it contributed to a paradigm shift in worldwide stroke guidelines, greatly expanding the therapeutic window and treatment options for devastating strokes.
Historical Context
Prior to 2015, three major trials (IMS III, MR RESCUE, and SYNTHESIS Expansion) failed to demonstrate the superiority of endovascular therapy over medical management, largely due to the use of older, less effective devices, long procedure times, and inconsistent use of vascular imaging to confirm large vessel occlusion. The introduction of highly effective stent retrievers and improved workflow protocols led to a wave of trials in late 2014 and 2015 (MR CLEAN, ESCAPE, EXTEND-IA, SWIFT PRIME, and REVASCAT) that collectively revolutionized modern neurointerventional care.
Guided Discussion
High-yield insights from every perspective
The REVASCAT trial specifically enrolled patients with acute ischemic stroke due to anterior circulation occlusion. Which key blood vessels are included in the anterior circulation, and what classic clinical deficits would you expect to see in a patient presenting with an occlusion in this territory?
Key Response
This question tests foundational neuroanatomy and clinical reasoning. The anterior circulation primarily involves the internal carotid artery (ICA) and the middle cerebral artery (MCA). Students must connect this anatomy to classic stroke syndromes, such as contralateral hemiparesis, hemisensory loss, and cortical signs like aphasia (dominant hemisphere) or neglect (nondominant hemisphere), which are crucial for identifying thrombectomy candidates clinically.
Patient selection in the REVASCAT trial required an ASPECTS (Alberta Stroke Program Early CT Score) of greater than 7 on non-contrast head CT. How is the ASPECTS score calculated, and why is it a critical factor in the decision to proceed with mechanical thrombectomy in the acute setting?
Key Response
Residents must know how to clinically apply imaging criteria. ASPECTS is a 10-point quantitative topographic CT scan score used to assess early ischemic changes in the MCA territory. A higher score (e.g., >7) indicates a smaller core of established infarction. Intervening on patients with low ASPECTS (large established infarcts) increases the risk of hemorrhagic transformation and reduces the probability of a favorable functional outcome, making it a key triage tool.
Unlike EXTEND-IA which heavily relied on CT perfusion to identify target mismatch, REVASCAT permitted enrollment up to 8 hours using non-contrast CT and CTA without requiring advanced perfusion imaging. How does reliance on CT/CTA versus CT perfusion alter the workflow, patient selection, and the physiological profile (core-to-penumbra ratio) of the cohort selected for intervention?
Key Response
Fellows need to navigate the nuances of stroke imaging protocols. Relying solely on CT/CTA is faster and more universally available, potentially accelerating door-to-puncture times. However, without perfusion imaging to confirm a salvageable penumbra, there is a risk of including 'fast progressors' who have already completed their infarct by hour 6 or 7, diluting the treatment effect. Comparing these trial designs highlights the balance between procedural speed and physiological precision.
The REVASCAT trial was terminated early due to a loss of clinical equipoise following the publication of other seminal endovascular trials like MR CLEAN and ESCAPE. How does early trial termination affect the magnitude of the observed treatment effect, and how should this statistical phenomenon influence how you counsel patients and families regarding expected outcomes?
Key Response
This addresses 'truncation bias.' Trials stopped early for benefit often overestimate the true treatment effect because they are halted at a random high point in the data curve. Attendings must critically integrate this into their practice, understanding that while thrombectomy is highly effective, the real-world effect sizes might be slightly more modest than those reported in early-terminated trials, which is vital for setting realistic expectations during family counseling.
Scholarly Review
Critical appraisal through the lens of expert reviewers and guideline development
The primary outcome in REVASCAT was evaluated using a shift analysis (ordinal logistic regression) of the modified Rankin scale (mRS) at 90 days. What are the statistical assumptions underlying the proportional odds model used in this analysis, and how might violations of these assumptions compromise the interpretation of the common odds ratio?
Key Response
This probes advanced statistical methodology. Ordinal logistic regression relies on the proportional odds assumption, meaning the treatment effect (odds ratio) is assumed to be identical across all cut-points of the mRS. If the intervention drastically improves mortality but does not shift moderate disability to mild disability, this assumption is violated, and reporting a single common odds ratio becomes mathematically invalid and clinically misleading.
Given that the control arm (medical therapy) in REVASCAT did not undergo a sham endovascular procedure, both patients and treating clinicians were inevitably unblinded to the treatment allocation. As a reviewer evaluating this manuscript, what specific methodological safeguards would you demand to mitigate the risk of performance and detection bias, particularly regarding the 90-day mRS assessment?
Key Response
Journal editors must critically appraise study design flaws. The lack of a sham procedure necessitates a PROBE (Prospective Randomized Open, Blinded End-point) design. A rigorous reviewer would flag the need for strict, documented blinding of the neurologists or outcome assessors who score the 90-day mRS, and would scrutinize whether differential post-acute care (e.g., more aggressive rehab for the intervention arm) might confound the functional outcomes.
REVASCAT provided strong evidence for mechanical thrombectomy up to 8 hours from symptom onset, bridging the gap between the 6-hour window of MR CLEAN and the later extended-window trials. How does this specific 8-hour evidence integrate into current AHA/ASA stroke guidelines, and how does the level of recommendation for the 6-to-8 hour window differ from the 0-to-6 hour and 6-to-24 hour windows?
Key Response
Guideline committees must synthesize timelines and levels of evidence. AHA/ASA guidelines currently give a Class I recommendation for thrombectomy within 6 hours. REVASCAT's data helped support recommendations extending beyond 6 hours. However, the guidelines differentiate the 6-24 hour window (based on DAWN and DEFUSE 3), which strictly requires advanced perfusion or clinical-core mismatch imaging. Discussing how REVASCAT fits into this continuum is essential for shaping actionable, time-tiered clinical practice guidelines.
Clinical Landscape
Noteworthy Related Trials
MR CLEAN Trial
Tested
Intraarterial treatment (thrombectomy) plus usual care
Population
Acute ischemic stroke patients with anterior circulation proximal arterial occlusion within 6 hours
Comparator
Usual care alone (including IV alteplase)
Endpoint
Modified Rankin scale (mRS) score at 90 days
ESCAPE Trial
Tested
Endovascular treatment plus standard care
Population
Acute ischemic stroke patients with proximal anterior circulation occlusion up to 12 hours from onset
Comparator
Standard care alone
Endpoint
Modified Rankin scale (mRS) score at 90 days
DAWN Trial
Tested
Endovascular thrombectomy plus standard medical care
Population
Acute ischemic stroke patients with clinical-core mismatch 6 to 24 hours from onset
Comparator
Standard medical care alone
Endpoint
Rate of functional independence at 90 days
Tailored to your role
Want this tailored to you?
Add your specialty or training stage to get role-specific takeaways and more questions.
Personalize this analysis